BioAge Labs, Inc. Insider Trading

BIOA

Last 12 months

Insiders sold $7.79M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Oct 2024.

Net open-market

−$7.79M

0 buys · 9 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Oct 2024

Oct 3, 2024

Get an email when BIOA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 29 – 30	Shane Barton Principal Accounting Officer	Sold10b5-1 plan 2 parts	62,566	$25.20 average	$1.58M	100%	Form 4
Apr 1	Paul D Rubin Chief Medical Officer	Sold10b5-1 plan	8,820	$17.81	157K	100%	Form 4
Mar 2	Paul D Rubin Chief Medical Officer	Sold10b5-1 plan	7,433	$20.30	151K	100%	Form 4
Feb 2	Paul D Rubin Chief Medical Officer	Sold10b5-1 plan	7,433	$18.75	139K	100%	Form 4
Jan 13	Kristen Fortney Chief Executive Officer	Sold10b5-1 plan	233,107	$18.12	$4.22M	19%	Form 4
Jan 13	Dov A Md Goldstein Chief Financial Officer	Sold10b5-1 plan 4 parts	27,000	$19.70 average	532K	55%	Form 4
Jan 2	Paul D Rubin Chief Medical Officer	Sold10b5-1 plan	7,433	$12.85	96K	100%	Form 4
Dec 9, 2025	Paul D Rubin Chief Medical Officer	Sold10b5-1 plan	18,000	$12.00	216K	100%	Form 4
Dec 4, 2025	Paul D Rubin Chief Medical Officer	Sold10b5-1 plan	68,897	$10.19	702K	100%	Form 4

Jun 29 – 3010b5-1 plan
Shane Barton
Principal Accounting Officer · sold 62,566 at avg $25.20
$1.58M
100% of stake
Apr 110b5-1 plan
Paul D Rubin
Chief Medical Officer · sold 8,820 at $17.81
157K
100% of stake
Mar 210b5-1 plan
Paul D Rubin
Chief Medical Officer · sold 7,433 at $20.30
151K
100% of stake
Feb 210b5-1 plan
Paul D Rubin
Chief Medical Officer · sold 7,433 at $18.75
139K
100% of stake
Jan 1310b5-1 plan
Kristen Fortney
Chief Executive Officer · sold 233,107 at $18.12
$4.22M
19% of stake
Jan 1310b5-1 plan
Dov A Md Goldstein
Chief Financial Officer · sold 27,000 at avg $19.70
532K
55% of stake
Jan 210b5-1 plan
Paul D Rubin
Chief Medical Officer · sold 7,433 at $12.85
96K
100% of stake
Dec 9, 202510b5-1 plan
Paul D Rubin
Chief Medical Officer · sold 18,000 at $12.00
216K
100% of stake
Dec 4, 202510b5-1 plan
Paul D Rubin
Chief Medical Officer · sold 68,897 at $10.19
702K
100% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BIOA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with BIOA

CompareIntrinsic value

ZBIOZenas BioPharma, Inc.

$28.46+0.28%10

EVMNEvommune, Inc.

$6.04+1.68%35

CBIOCrescent Biopharma, Inc.

$13.42+2.76%50

IRDOpus Genetics Inc.

$4.27+8.65%10

PGENPrecigen Inc.

$5.06-3.71%0

ISCOInternational Stem Cell Corporation

$0.14+0.00%29

HOOKHookipa Pharma Inc.

No recent price20

ACRSAclaris Therapeutics, Inc.

$3.68-1.60%10

Held by ETFs

BIOA is in 12 US ETFs. The largest of them, with BIOA's weight in each:

Spot a number that looks wrong? Check it in BIOA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BIOA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.